Literature DB >> 17275731

Targeting mammalian target of rapamycin (mTOR) for health and diseases.

Chi Kwan Tsang1, Haiyan Qi, Leroy F Liu, X F Steven Zheng.   

Abstract

The macrolide rapamycin is used clinically to treat graft rejection and restenosis. Mammalian target of rapamycin (mTOR) is a central controller of cellular and organism growth that integrates nutrient and hormonal signals, and regulates diverse cellular processes. New studies have linked mTOR to several human diseases including cancer, diabetes, obesity, cardiovascular diseases and neurological disorders. Recent data have also revealed that mTOR is involved in the regulation of lifespan and in age-related diseases. These findings demonstrate the importance of growth control in the pathology of major diseases and overall human health, and underscore the therapeutic potential of the mTOR pathway.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17275731     DOI: 10.1016/j.drudis.2006.12.008

Source DB:  PubMed          Journal:  Drug Discov Today        ISSN: 1359-6446            Impact factor:   7.851


  147 in total

1.  Integration analysis of quantitative proteomics and transcriptomics data identifies potential targets of frizzled-8 protein-related antiproliferative factor in vivo.

Authors:  Wei Yang; Yongsoo Kim; Taek-Kyun Kim; Susan K Keay; Kwang Pyo Kim; Hanno Steen; Michael R Freeman; Daehee Hwang; Jayoung Kim
Journal:  BJU Int       Date:  2012-06-28       Impact factor: 5.588

2.  Conservation, duplication, and loss of the Tor signaling pathway in the fungal kingdom.

Authors:  Cecelia A Shertz; Robert J Bastidas; Wenjun Li; Joseph Heitman; Maria E Cardenas
Journal:  BMC Genomics       Date:  2010-09-23       Impact factor: 3.969

3.  Prion-like mechanisms in epileptogenesis.

Authors:  F Orzi; B Casolla; R Rocchi; F Fornai
Journal:  Neurol Sci       Date:  2012-07-10       Impact factor: 3.307

Review 4.  Tailoring mTOR-based therapy: molecular evidence and clinical challenges.

Authors:  Gaetano Santulli; Hana Totary-Jain
Journal:  Pharmacogenomics       Date:  2013-09       Impact factor: 2.533

Review 5.  Targeted medical therapy of biliary tract cancer: recent advances and future perspectives.

Authors:  Michael Hopfner; Detlef Schuppan; Hans Scherubl
Journal:  World J Gastroenterol       Date:  2008-12-14       Impact factor: 5.742

6.  Chronic mTOR inhibition by rapamycin induces muscle insulin resistance despite weight loss in rats.

Authors:  N Deblon; L Bourgoin; C Veyrat-Durebex; M Peyrou; M Vinciguerra; A Caillon; C Maeder; M Fournier; X Montet; F Rohner-Jeanrenaud; M Foti
Journal:  Br J Pharmacol       Date:  2012-04       Impact factor: 8.739

7.  Mechanisms of regulation of RNA polymerase III-dependent transcription by TORC1.

Authors:  Yuehua Wei; Chi Kwan Tsang; X F Steven Zheng
Journal:  EMBO J       Date:  2009-07-02       Impact factor: 11.598

Review 8.  Treatment of gastrointestinal neuroendocrine tumors with inhibitors of growth factor receptors and their signaling pathways: recent advances and future perspectives.

Authors:  Michael Höpfner; Detlef Schuppan; Hans Scherübl
Journal:  World J Gastroenterol       Date:  2008-04-28       Impact factor: 5.742

9.  Activation of the AKT and mammalian target of rapamycin pathways and the inhibitory effects of rapamycin on those pathways in canine malignant melanoma cell lines.

Authors:  Michael S Kent; Cameron J Collins; Fang Ye
Journal:  Am J Vet Res       Date:  2009-02       Impact factor: 1.156

10.  mTORC1 and p53: clash of the gods?

Authors:  Paul Hasty; Zelton Dave Sharp; Tyler J Curiel; Judith Campisi
Journal:  Cell Cycle       Date:  2013-01-01       Impact factor: 4.534

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.